Absci Corporation Achieves Milestone with Phase 1 Trial of Anti-TL1A Antibody for IBD
Absci Corporation has announced a milestone in its clinical trial of ABS-101, a potential treatment for Inflammatory Bowel Disease, and reported stronger-than-expected financial performance for Q1 2025.
2 minutes to read